|
|
|
Volumn 16, Issue 2, 1998, Pages 113-117
|
|
Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC)
a
|
|
Author keywords
Epstein Barr virus (EBV); Nasopharyngeal carcinoma (NPC); Radiotherapy; Viral capsid antigen (VCA)
|
|
Indexed keywords
VIRUS ANTIBODY;
VIRUS CAPSID ANTIGEN;
ADULT;
AGED;
ANTIBODY TITER;
ARTICLE;
BURKITT LYMPHOMA;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED STUDY;
DIAGNOSTIC VALUE;
DISEASE MARKER;
EPSTEIN BARR VIRUS;
FEMALE;
HISTOPATHOLOGY;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
NASOPHARYNX CARCINOMA;
PATIENT MONITORING;
PROGNOSIS;
RADIATION DOSE;
TREATMENT OUTCOME;
VIRUS DETECTION;
ADULT;
AGED;
ANTIBODIES, VIRAL;
DISEASE-FREE SURVIVAL;
FEMALE;
FOLLOW-UP STUDIES;
HERPESVIRIDAE INFECTIONS;
HERPESVIRUS 4, HUMAN;
HUMANS;
IMMUNOENZYME TECHNIQUES;
IMMUNOGLOBULIN A;
IMMUNOGLOBULIN G;
MALE;
MIDDLE AGED;
NASOPHARYNGEAL NEOPLASMS;
PROGNOSIS;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
TUMOR VIRUS INFECTIONS;
VIRAL MATRIX PROTEINS;
|
|
EID: 0031862316
PISSN: 02882043
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (23)
|
|
References (20)
|
